

Oral Obesity Drugs Market - 2026-2035

<https://marketpublishers.com/r/O8A9026F2F89EN.html>

Date: June 2026

Pages: 44

Price: US\$ 3,400.00 (Single User License)

ID: O8A9026F2F89EN

Abstracts

Oral Obesity Drugs Market reached US\$ 4.43 billion in 2025 and is expected to reach US\$ 58.91 billion by 2035, growing with a CAGR of 27.84% during the forecast period 2026-2035.

The Oral Obesity Drugs Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.

A Oral Obesity Drugs Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.

By Drug Class

GLP-1 Receptor Agonists*

Dual Incretin Agonists

Triple Agonists

Amylin-Based Drugs

Lipase Inhibitors

CNS-Acting Anti-Obesity Drugs

Melanocortin-4 Receptor Agonists

Others

By Molecule Type

Small Molecules*

Peptide-Based Molecules

Peptidomimetics

Others

By Product Type

Branded *

Generic

By Prescription Type

Prescribed*

OTC

By Patient Group

Adolescents*

Adults

Geriatric

By Indication

Obesity*

Overweight with Comorbidities

Obesity with Type 2 Diabetes

Obesity with Cardiovascular Risk

Obesity with Metabolic Syndrome

Others

By Distribution Channel

Hospital Pharmacies*

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Specialty Pharmacies

Telehealth

Others

By End-User

Hospitals*

Obesity and Weight Management Clinics

Endocrinology Clinics

Homecare Settings

Others

Regional Analysis for Oral Obesity Drugs Market:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

This Report Covers:

Go-to-market Strategy.

Neutral perspective on the market performance.

Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

Customized regional/country reports as per request and country level analysis.

Potential & niche segments and regions exhibiting promising growth covered.

Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Research Process:

Both primary and secondary data sources have been used in the global Oral Obesity Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Data
 - 1.1.1. Secondary Data
 - 1.1.2. Primary Data
 - 1.1.3. CAGR Analysis
- 1.2. Market Size Estimation Methodology
 - 1.2.1. Bottom-Up Approach
 - 1.2.2. Top-Down Approach
- 1.3. Market Breakdown & Data Triangulation
- 1.4. Research Assumptions
- 1.5. Limitations

2. DEFINITION AND OVERVIEW

- 2.1. Study Objectives
- 2.2. Market Definition
- 2.3. Market Scope
- 2.4. Stakeholder Analysis
- 2.5. Currency Considered
- 2.6. Study Period

3. EXECUTIVE SUMMARY

- 3.1. Key Takeaways
- 3.2. Top To Bottom Analysis
- 3.3. Market Share Analysis
- 3.4. Data Points from Key Primary Interviews
- 3.5. Data Points from Key Secondary Databases
- 3.6. Market Snapshot
- 3.7. Geographical Snapshot

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Injection Fatigue Creating a Clear Commercial Opening for Oral Obesity

Therapies

4.1.1.2. Obesity's Shift from Lifestyle Concern to Chronic Disease Expanding Prescriber Confidence

4.1.1.3. Oral GLP-1 and Multi-Agonist Pipelines Redefining the Next Wave of Metabolic Drug Competition

4.1.2. Restraints

4.1.2.1. Payer Resistance to Long-Term Weight-Loss Drug Coverage Limiting Mass Adoption

4.1.2.2. Safety, Tolerability and Weight-Regain Concerns Creating Pressure for Stronger Real-World Evidence

4.1.3. Impact Analysis - Drivers and Restraints

4.1.4. Opportunity

4.1.4.1. Primary Care and Telehealth Channels Opening Scalable Access Beyond Specialist-Led Obesity Treatment

4.1.4.2. Cardiometabolic Outcome Positioning Creating a Stronger Reimbursement Case Beyond Weight Loss

4.1.5. Trends

4.1.5.1. Small-Molecule Oral GLP-1 Drugs Emerging as a Strategic Alternative to Peptide-Based Injectable Dominance

4.1.5.2. Drug Developers Moving from Weight-Loss Claims Toward Broader Metabolic, Cardiovascular and MASH Value Propositions

4.1.6. Challenges

5. INDUSTRY ANALYSIS

5.1. Porter's Five Force Analysis

5.2. Political Factors

5.3. Social Factors

5.3.1. Patients Are Increasingly Seeking Non-Injectable Weight-Loss Options That Fit Daily Treatment Routines More Easily

5.3.2. Growing Medical Acceptance of Obesity as a Treatable Disease Is Reducing Stigma Around Prescription Weight-Loss Drugs

5.3.3. Long-Term Treatment Fatigue with Injectable Therapies Is Creating Space for Oral Obesity Drugs with Better Convenience and Adherence

5.4. Economic Factors

5.4.1. Large Untreated Obese and Overweight Patient Pool Is Creating a High-Value Expansion Opportunity for Oral Drug Manufacturers

5.4.2. Premium Drug Pricing and Long-Term Therapy Costs Are Increasing Payer Pushback and Patient Affordability Challenges

5.4.3. Big Pharma Investment Is Intensifying Around Oral GLP-1, Dual Incretin and Triple Agonist Obesity Pipelines

5.5. Geopolitical Factors

5.6. Supply/Value Chain Analysis

5.7. Pricing Analysis

5.8. Regulatory Analysis

5.9. Technology Landscape

5.10. Innovation & R&D Trends

5.11. Sustainability and ESG Analysis

5.12. Risk Avoidance Model

5.13. Go-To-Market (GTM) Strategy

5.14. BCG Matrix

5.15. Business Models Analysis

5.16. Demand-Supply Gap

5.17. Risk Mitigation Framework

5.18. Compliance Roadmap

5.19. Strategic Implications

5.20. Emerging Opportunities

5.21. Adoption Trends

5.22. Disruption Analysis

5.23. DMI Opinion

6. BY DRUG CLASS

6.1. Introduction

6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

6.1.2. Market Attractiveness Index, By Drug Class

6.2. GLP-1 Receptor Agonists*

6.2.1. Introduction

6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

6.3. Dual Incretin Agonists

6.4. Triple Agonists

6.5. Amylin-Based Drugs

6.6. Lipase Inhibitors

6.7. CNS-Acting Anti-Obesity Drugs

6.8. Melanocortin-4 Receptor Agonists

6.9. Others

7. BY MOLECULE TYPE

7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type

7.1.2. Market Attractiveness Index, By Molecule Type

7.2. Small Molecules*

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

7.3. Peptide-Based Molecules

7.4. Peptidomimetics

7.5. Others

8. BY PRODUCT TYPE

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

8.1.2. Market Attractiveness Index, By Product Type

8.2. Branded *

8.2.1. Introduction

8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

8.3. Generic

9. BY PRESCRIPTION TYPE

9.1. Introduction

9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Prescription Type

9.1.2. Market Attractiveness Index, By Prescription Type

9.2. Prescribed*

9.2.1. Introduction

9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

9.3. OTC

10. BY PATIENT GROUP

10.1. Introduction

10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Group

10.1.2. Market Attractiveness Index, By Patient Group

10.2. Adolescents*

10.2.1. Introduction

10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

10.3. Adults

10.4. Geriatric

11. BY INDICATION

11.1. Introduction

11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

11.1.2. Market Attractiveness Index, By Indication

11.2. Obesity*

11.2.1. Introduction

11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

11.3. Overweight with Comorbidities

11.4. Obesity with Type 2 Diabetes

11.5. Obesity with Cardiovascular Risk

11.6. Obesity with Metabolic Syndrome

11.7. Others

12. BY DISTRIBUTION CHANNEL

12.1. Introduction

12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12.1.2. Market Attractiveness Index, By Distribution Channel

12.2. Hospital Pharmacies*

12.2.1. Introduction

12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

12.3. Hospital Pharmacies

12.4. Retail Pharmacies

12.5. Online Pharmacies

12.6. Specialty Pharmacies

12.7. Telehealth

12.8. Others

13. BY END-USER

13.1. Introduction

13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

13.1.2. Market Attractiveness Index, By End-User

13.2. Hospitals*

13.2.1. Introduction

- 13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 13.3. Obesity and Weight Management Clinics
- 13.4. Endocrinology Clinics
- 13.5. Homecare Settings
- 13.6. Others

14. BY REGION

14.1. Introduction

- 14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 14.1.2. Market Attractiveness Index, By Region

14.2. North America*

- 14.2.1. Introduction
- 14.2.2. Key Region-Specific Dynamics
- 14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
- 14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 14.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Prescription Type
- 14.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Group
- 14.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 14.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 14.2.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 14.2.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 14.2.11.1. U.S.
 - 14.2.11.2. Canada
 - 14.2.11.3. Mexico

14.3. Europe

- 14.3.1. Introduction
- 14.3.2. Key Region-Specific Dynamics
- 14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
- 14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 14.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Prescription Type
- 14.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Group
- 14.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 14.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 14.3.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 14.3.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 14.3.11.1. Germany

- 14.3.11.2. UK
- 14.3.11.3. France
- 14.3.11.4. Russia
- 14.3.11.5. Spain
- 14.3.11.6. Italy
- 14.3.11.7. Poland
- 14.3.11.8. Rest of Europe
- 14.4. Latin America
 - 14.4.1. Introduction
 - 14.4.2. Key Region-Specific Dynamics
 - 14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
 - 14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
 - 14.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Prescription Type
 - 14.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Group
 - 14.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
 - 14.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 14.4.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
 - 14.4.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 14.4.11.1. Brazil
 - 14.4.11.2. Argentina
 - 14.4.11.3. Rest of Latin America
- 14.5. Asia-Pacific
 - 14.5.1. Introduction
 - 14.5.2. Key Region-Specific Dynamics
 - 14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
 - 14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
 - 14.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Prescription Type
 - 14.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Group
 - 14.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
 - 14.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 14.5.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
 - 14.5.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 14.5.11.1. China
 - 14.5.11.2. India
 - 14.5.11.3. Japan
 - 14.5.11.4. Australia
 - 14.5.11.5. South Korea

- 14.5.11.6. Indonesia
- 14.5.11.7. Malaysia
- 14.5.11.8. Rest of Asia-Pacific
- 14.6. Middle East and Africa
 - 14.6.1. Introduction
 - 14.6.2. Key Region-Specific Dynamics
 - 14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
 - 14.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
 - 14.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Prescription Type
 - 14.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Group
 - 14.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
 - 14.6.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 14.6.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
 - 14.6.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 14.6.11.1. UAE
 - 14.6.11.2. Saudi Arabia
 - 14.6.11.3. South Africa
 - 14.6.11.4. Israel
 - 14.6.11.5. Turkiye
 - 14.6.11.6. Rest of Middle East and Africa

15. COMPETITIVE LANDSCAPE

- 15.1. Competitive Scenario
- 15.2. Market Share Analysis - Global
- 15.3. Market Share Analysis - North America
- 15.4. Market Share Analysis - Europe
- 15.5. Market Share Analysis - Asia-Pacific
- 15.6. Mergers and Acquisitions Analysis
- 15.7. Partner Identification Analysis
- 15.8. Investment & Funding Landscape
- 15.9. Strategic Alliances & Innovation Pipeline

16. COMPANY PROFILES

- 16.1. Novo Nordisk A/S*
 - 16.1.1. Company Overview
 - 16.1.2. Product Portfolio and Description

- 16.1.3. Revenue Analysis
- 16.1.4. Pricing Analysis
- 16.1.5. SWOT Analysis
- 16.1.6. Recent Developments
 - 16.1.6.1. Major Deals
 - 16.1.6.2. M&A
 - 16.1.6.3. Collaboration
 - 16.1.6.4. Acquisition
 - 16.1.6.5. Joint Ventures
 - 16.1.6.6. Innovations
- 16.1.7. Recent News
 - 16.1.7.1. Events
 - 16.1.7.2. Conferences
 - 16.1.7.3. Symposiums
 - 16.1.7.4. Webinars

17. LILLY USA, LLC LIST NOT EXHAUSTIVE

- 17.1. F. Hoffmann-La Roche Ltd
- 17.2. VIVUS LLC
- 17.3. Currax Pharmaceuticals LLC
- 17.4. Haleon
- 17.5. Structure Therapeutics
- 17.6. Viking Therapeutics
- 17.7. AstraZeneca
- 17.8. Merck & Co., Inc.

18. APPENDIX

- 18.1. About Us and Services
- 18.2. Contact Us

I would like to order

Product name: Oral Obesity Drugs Market - 2026-2035

Product link: <https://marketpublishers.com/r/O8A9026F2F89EN.html>

Price: US\$ 3,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O8A9026F2F89EN.html>